Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy

Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy

BackgroundPrimary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths globally. Despite advances in targeted therapy and immunotherapy, survival rates for advanced HCC remain low. Combining hepatic artery infusion chemotherapy (HAIC) with systemic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Nutrition
Subjects:	sarcopenia myosteatosis hepatocellular carcinoma hepatic arterial infusion chemotherapy targeted therapy immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2025.1586202/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
by: Weihao Zhang, et al.
Published: (2025-06-01)

Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review
by: Ying Wu, et al.
Published: (2025-03-01)

Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies
by: Hao-Huan Tang, et al.
Published: (2025-04-01)

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update
by: Shiguang Chen, et al.
Published: (2025-12-01)

Myosteatosis predicts the prognosis of patients with ST-elevation myocardial infarction who undergo emergency percutaneous coronary intervention
by: Junqian Wang, et al.
Published: (2025-03-01)

Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study
by: Hao-yang Tan, et al.
Published: (2025-05-01)

Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma: A Three-Dimensional Visualization Perspective
by: Tan Y, et al.
Published: (2025-04-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01)

Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements
by: Wei Xu, et al.
Published: (2025-05-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
by: Zizhuo Wang, et al.
Published: (2025-01-01)

Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report
by: Miao Li, et al.
Published: (2024-12-01)

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma
by: Li J, et al.
Published: (2025-02-01)

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab
by: Chang-Fu Liu, et al.
Published: (2025-08-01)

Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma
by: Xia Y, et al.
Published: (2025-07-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-12-01)

Association between myosteatosis or sarcopenia based on abdominal CT and hypertension in systemic lupus erythematosus patients
by: Bowen Wang, et al.
Published: (2025-03-01)

All you need to know about sarcopenia: a short guide for an internal medicine physician in questions and answers
by: G. R. Bikbavova, et al.
Published: (2023-10-01)

CT‐Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies
by: Smith Giri, et al.
Published: (2025-02-01)

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma
by: Yu-zhe Cao, et al.
Published: (2024-11-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)Research in context
by: Wei Gao, et al.
Published: (2025-05-01)

A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma
by: Xing-Yan Le, et al.
Published: (2025-05-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Prognostic Role of Sarcopenia in High-grade Lymphoma: A Retrospective PET/CT-Based Study
by: Özlem Beyler, et al.
Published: (2025-08-01)

Parameters of Body Composition Predict Clinical Course in Acute Colonic Diverticulitis
by: Alexey Surov, et al.
Published: (2025-06-01)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio in Patients with Hepatocellular Carcinoma Receiving HAIC-Based Conversion Hepatectomy: A Dual-Center Retrospective Cohort Study
by: Li D, et al.
Published: (2025-07-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2025-05-01)

Postoperative adjuvant hepatic arterial infusion chemotherapy with gemcitabine-cisplatin sequential capecitabine combined with PDL1 inhibitors in resected high-risk intrahepatic cholangiocarcinom: study protocol for a prospective, multicenter, single-arm, phase 2 trial (HgcCP trial)
by: Ying Yang, et al.
Published: (2025-07-01)

AI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy
by: Zhou Y, et al.
Published: (2025-07-01)

Radiotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion chemotherapy of RALOX versus FOLFOX for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score-matching cohort study
by: Hao-yang Tan, et al.
Published: (2025-05-01)

Single‐Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy
by: YeXing Huang, et al.
Published: (2025-02-01)

Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis
by: Zhong S, et al.
Published: (2025-03-01)

PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy
by: Fei Cao, et al.
Published: (2025-06-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Exploration of Fully‐Automated Body Composition Analysis Using Routine CT‐Staging of Lung Cancer Patients for Survival Prognosis
by: Marc‐David Künnemann, et al.
Published: (2025-08-01)

Different cutoff values of the skeletal muscle mass and myosteatosis result in different clinical impact on overall survival in oncology. A subanalysis of a clinical trial
by: Alexey Surov, et al.
Published: (2025-04-01)